MOTS-c and GLP-1 come up together over the muscle and metabolic loss of rapid weight loss.
- It switched on AMPK, the pathway exercise uses, in cells and mice.
- The FDA found no human data and no toxicity studies on it.
- An FDA committee backed it narrowly in July 2026, and an HHS policy has covered compounding it since 28 October 2026.

The conversation around MOTS-c and GLP-1 medications has grown steadily in research and biohacking communities, mostly because both target the same underlying problem. GLP-1 medications produce large weight loss, and part of what comes off is lean mass rather than fat. MOTS-c gets attention because, in mice, it acted mainly on skeletal muscle, the tissue GLP-1 users most want to keep.
Regulatory status varies by country, and everything below describes the US position. Australian residents should consult TGA guidance, and UK residents MHRA guidance.
On 23 July 2026, the FDA’s advisory committee recommended MOTS-c for the 503A compounding list in a narrow vote, as Pharmaceutical Executive reported. The FDA has posted no minutes, so the official record is the meeting video. The FDA’s own reviewers had recommended against all seven peptides under review, and the law firm Mintz counted six of the seven backed across the two days, with only emideltide turned down.
The next step still sits with the FDA. It can add the peptide to the list by rulemaking or move it into Category 1 of its interim enforcement policy, the other route Mintz names, and the FDA’s own 503A page still shows a list amendment it proposed in 2019 waiting for a final rule. Since 28 October 2026, an HHS interim policy says HHS does not intend to take enforcement action against pharmacies that compound MOTS-c as an injection under the skin or into muscle, under ten conditions. Full detail is in the July 2026 peptide FDA decision.
Table of Contents
Disclosure: This article contains affiliate links. If you purchase through these links I may earn a small commission at no extra cost to you.
What Is MOTS-c?
MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA Type-c. That name is not going to come up in conversation, but what it describes matters: MOTS-c is a 16-amino acid peptide encoded directly within mitochondrial DNA, discovered in 2015 by a team at the University of Southern California.
What makes it unusual is where it comes from. Most peptides are encoded in the cell’s nuclear DNA. MOTS-c is one of a small class called mitochondria-derived peptides, meaning it’s produced inside the mitochondria themselves. Mitochondria were once considered passive energy factories. The discovery of peptides like MOTS-c changed that picture considerably, revealing that mitochondria actively signal to the rest of the body about metabolic conditions.
MOTS-c is sometimes described as an “exercise mimetic” because in cell and mouse studies it activated AMPK, the same cellular energy-sensing pathway that exercise triggers. AMPK activation improves glucose uptake, increases fat oxidation, and supports insulin sensitivity. These are all effects that exercise produces, which is how the “mimics exercise” framing entered the literature.
What Does MOTS-c and GLP-1 Research Show?
The foundational research on MOTS-c comes from Lee and colleagues’ 2015 paper in Cell Metabolism, which reported that the peptide regulates insulin sensitivity and metabolic balance, with skeletal muscle as its apparent main target and AMPK activation at the end of its pathway. In mice, MOTS-c treatment prevented diet-induced obesity and the insulin resistance (cells responding poorly to insulin) that came with a high-fat diet and with age. Those are strong preclinical findings, and they are why MOTS-c drew interest as a possible drug.
A 2023 review published in the Journal of Translational Medicine summarised the research so far: MOTS-c levels fall with age, stress and exercise switch the peptide on, and giving it to animals improved metabolic markers linked to obesity and insulin resistance.
The connection between MOTS-c and GLP-1 treatment becomes clearer when you look at what GLP-1 medications do to lean mass. Body scans can measure how much of that loss is lean tissue. In a substudy of the tirzepatide trial SURMOUNT-1, published in Diabetes, Obesity and Metabolism, about a quarter of the weight lost was lean mass, the same share as on placebo and close to what dieting alone produces. Lean mass is everything that is not fat or bone, organs and water included, so it overstates muscle. The risk is still real. It matters if you are deciding how hard to work at protecting muscle.
The loss is partly a consequence of rapid calorie restriction and partly a function of the reduced appetite making it harder to hit protein targets.
The mechanism, and how much muscle GLP-1 users lose and what protects it, is covered separately.
In Lee’s mouse work, skeletal muscle appeared to be MOTS-c’s main target, and treated mice handled insulin better. Its levels also fall with age. For GLP-1 users in midlife or older who are managing both significant weight loss and muscle preservation, that overlap is the reason MOTS-c keeps appearing in conversations about what else might help.
The caveat is a large one. The FDA’s briefing document for the July 2026 meeting found the effectiveness studies “limited to in-vitro and in-vivo rodent models”, no human data on any MOTS-c drug product, and molecular targets that “remain unknown”. The exercise-mimetic label describes one pathway in cells and mice. Nobody has shown it in people.
Steps 1, 2 and 4 are measured in people. Step 3 follows from step 2, and step 5 is animal and cell work.
What is available today acts on step 2. Resistance training and protein intake are the two interventions with human evidence behind them for protecting muscle.
How Does MOTS-c Relate to Metabolic Adaptation?
Large weight loss can trigger metabolic adaptation, where the body burns less at rest than its new size predicts. In 14 former contestants from the TV show The Biggest Loser, resting burn was still about 500 calories a day below that prediction six years later, a study in Obesity found. That study was of diet and exercise, not GLP-1 treatment, and how adaptation plays into weight loss plateaus on GLP-1 medications is covered separately.
MOTS-c works inside the mitochondria. Its AMPK activation affects how cells use glucose and fat for fuel, and the Journal of Translational Medicine review describes cell and animal studies in which it switched on genes for mitochondrial biogenesis, meaning the creation of new mitochondria. Whether that could counter metabolic adaptation in a person is untested.
That overlap is why MOTS-c comes up alongside GLP-1 treatment. The problem its research targets, a slower metabolism alongside lost muscle, is one that rapid weight loss can bring.
Is MOTS-c Safe?
Nobody knows, and the FDA says so plainly. Its briefing document found no toxicity or cancer studies of MOTS-c in animals and no clinical studies in people, and it concluded that the “potential safety risks associated with the use of MOTS-c in humans are unknown”.
Two concerns are named. A peptide given by injection can provoke an immune reaction, and the FDA flags that risk for the injected route people propose. It also points to possible impurities and to trouble pinning down exactly what the drug substance is. Those questions put MOTS-c on the FDA’s list of substances that may present significant safety risks until its nomination was withdrawn.
The FDA’s search of adverse event reports found none. With no MOTS-c product legally sold, that is an absence of reports, not evidence of safety.
What Is MOTS-c’s Current Regulatory Status in the US?
This is where accuracy matters more than optimism.
MOTS-c is not an FDA-approved drug. It is not on the 503A list, so compounding it rests on the HHS interim policy, and it is not a supplement you can buy over the counter. Its nomination for compounding was withdrawn, and the FDA’s safety-risks list, as of its 22 April 2026 update, places it in the table of substances withdrawn from category 2 by their nominators, with the note that the FDA “has not identified any human exposure data” on products containing it.
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) discussed MOTS-c-related bulk drug substances on July 23, 2026, as part of a review of several peptides proposed for the 503A Bulks List. BPC-157 and KPV were heard at the same meeting. The FDA’s meeting page for those two days names each substance and the use FDA evaluated for it, and for MOTS-c that was obesity and osteoporosis. That is closer to why GLP-1 users are interested in it than most of the seven peptides: BPC-157, for instance, was assessed only for ulcerative colitis.
The PCAC review is advisory. The committee issues recommendations; it does not make regulatory decisions. It recommended MOTS-c for inclusion on the 503A Bulks List, which puts the next move with the FDA, by rulemaking or a Category 1 decision, with no set timetable. July 2026 was not a legalisation date. It was the start of a process that may or may not lead to legal compounding availability, on a timeline that extends well beyond that meeting.
Some sites covering the July 2026 PCAC meeting framed it as a significant unlock for these peptides. That framing was premature then and it is still wrong now. The favourable advisory vote is meaningful, but it has not changed the legal status of anything, and it does not produce clinical access on any short timeline.
The FDA’s 503A bulk drug substances page explains the category system in detail for anyone wanting the regulatory specifics.
BPC-157, evaluated for ulcerative colitis, was on the same 23 July list, and so was KPV, evaluated for wound healing and inflammatory conditions and discussed in GLP-1 communities for gut side effects. Both were recommended too. The July 2026 peptide FDA decision covers what the full result means in practice.
What Happened With MOTS-c at the July 2026 FDA Meeting?
MOTS-c went before the FDA’s Pharmacy Compounding Advisory Committee (PCAC) on Day 1 (23 July 2026), after its nominator withdrew the nomination and the FDA took up the review itself, as the briefing document records. The committee recommended it for the 503A bulk-compounding list in a close vote.
That is advice to the FDA: nothing about legal compounding status changed on the day of the vote, no proposed rule on it had appeared in the Federal Register by 3 November 2026, and the FDA still has to act, by rulemaking or a Category 1 decision, on no set timetable, and it can land somewhere other than where the committee did.
What each recommendation triggers is set out on the July 2026 FDA peptide decision page. For the picture across all seven peptides, see the Peptides for GLP-1 Users guide.
What About Other Peptides Available Now?
The peptide category that applies to GLP-1 users is broader than MOTS-c alone, and regulatory status varies considerably across it.
GHK-Cu sits somewhere else. Topical copper peptide serums are sold over the counter as cosmetics, outside the compounding question altogether, because a skin-care product needs no pharmacy. The guide to what topical GHK-Cu has been tested for on GLP-1 skin sets out what a serum can and cannot do, and why injected GHK-Cu is a separate matter.
MOTS-c is in a different category entirely. Injectable, research-stage, under regulatory review, with no approved human dosing protocol and only the HHS interim policy as a compounding route. Contrasting these two is useful for understanding how varied the “peptide” label is when it comes to what’s accessible and what isn’t.
What Does This Mean for GLP-1 Users Right Now?
MOTS-c research is asking an important question about metabolism that goes well beyond the peptide itself: what happens to mitochondrial function and lean mass during rapid weight loss, and can that process be targeted?
Can you take MOTS-c while on a GLP-1?
This is the question people ask most, and the answer is that it has not been tested, and outside the grey market the only route to it is a prescription filled under the interim HHS policy of 28 October 2026. No trial has given MOTS-c to people taking a GLP-1 medication. That matters more here than it might elsewhere, because both act on the same metabolic machinery: a GLP-1 changes energy intake and insulin dynamics, and MOTS-c is proposed to act on insulin sensitivity and mitochondrial function. Two interventions aimed at overlapping pathways is exactly the situation where an interaction would matter, and it is the situation nobody has studied.
The stacks that pair MOTS-c with retatrutide add a drug with no US approval either, and whether the retatrutide sold online is real is its own question.
If you and a clinician still decide to try it, livevital.io is one telehealth service that offers MOTS-c on its own as an injection under the skin. Your intake goes to a licensed clinician first, and any prescription is filled by a licensed 503A compounding pharmacy. The clinician may decline, and the interaction question above still has no answer.
The muscle question stands whether or not you take MOTS-c, and it can be worked on now.
Resistance training and enough protein are the two measures with human evidence for protecting lean mass while weight comes off, and protein targets are hardest to hit when appetite is low. The evidence on protecting muscle on a GLP-1 is set out separately.
For the nutrient gaps you can act on now, the GLP-1 supplements to start with names the four it suggests and the doses to stay under.
If you are weighing any change to a GLP-1 routine, a baseline blood test gives you numbers to compare against later. Everlywell sells lab tests you order yourself, some collected at home and some drawn at a lab, so a starting figure is on file without waiting for an appointment. It tells you nothing about whether MOTS-c or any other peptide suits you, and a prescriber may want to order their own.
If you want to follow the MOTS-c regulatory situation, the July 2026 PCAC vote is behind you and the next meaningful checkpoint is the FDA’s own move. Watch for either a proposed rule, with the comment period that goes with it, or a move into Category 1 of the FDA’s interim policy, and for any change to the HHS policy once its comment period closes on 13 November 2026.
MOTS-c reflects real scientific interest in the metabolic cost of rapid weight loss, so far studied in cells and rodents. The peptide is worth understanding. It is not something to buy through unregulated channels, and any source telling you otherwise deserves scepticism.
When a trial reads out, a compounder pulls one of these compounds, or the FDA changes its position, you’ll hear it from me along with what it means for you. The change and its context arrive in one email.
Unsubscribe anytime.
References
- Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism, 2015;21:443-454. Two authors declared consulting for CohBar, Inc., and one held its stock. doi.org
- Wan W, et al. Mitochondria-Derived Peptide MOTS-c: Effects and Mechanisms Related to Stress, Metabolism and Aging. Journal of Translational Medicine, 2023;21:36. ncbi.nlm.nih.gov
- US Food and Drug Administration. FDA Briefing Document for MOTS-c-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, 23-24 July 2026. fda.gov
- US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, updated 22 April 2026. fda.gov
- US Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov
- Pharmaceutical Executive. FDA Panel Votes to Loosen Restrictions for Four Peptides. 24 July 2026. pharmexec.com
- Mintz. FDA’s Advisory Committee Votes on Peptides: What It Does and Doesn’t Do. 29 July 2026. mintz.com
- Look M, et al. Body Composition Changes During Weight Reduction With Tirzepatide in the SURMOUNT-1 Study of Adults With Obesity or Overweight. Diabetes, Obesity and Metabolism, 2025;27:2720. Funded by Eli Lilly and Company, which makes tirzepatide; SURMOUNT-1 was double-blind and placebo-controlled. pmc.ncbi.nlm.nih.gov
- Fothergill E, et al. Persistent Metabolic Adaptation 6 Years After “The Biggest Loser” Competition. Obesity, 2016;24:1612-1619. pmc.ncbi.nlm.nih.gov
